Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A cost-effectiveness analysis of adrenalectomy for nonfunctional adrenal incidentalomas: is there a size threshold for resection?
[adrenal incidentaloma]
Adrenocortical
carcinoma
(
ACC
)
is
a
rare
,
but
aggressive
,
malignancy
.
Current
American
Association
of
Clinical
Endocrinologists
(
AACE
)
/
American
Association
of
Endocrine
Surgeons
(
AAES
)
guidelines
recommend
resection
of
nonfunctional
adrenal
neoplasms
≥
4
cm
.
This
study
evaluates
the
cost-effectiveness
of
this
approach
.
A
decision
tree
was
constructed
for
patients
with
a
nonfunctional
,
4
-
cm
adrenal
incidentaloma
with
no
radiographic
suspicion
for
ACC
.
Patients
were
randomized
to
adrenalectomy
,
surveillance
per
AACE
/
AAES
guidelines
,
or
no
follow-up
(
"
sign-off
"
)
.
Incremental
cost-effectiveness
ratio
(
ICER
)
includes
health
care
costs
,
including
missed
ACC
.
ICER
(
dollar
/
life-
year
-saved
[
LYS
]
)
was
determined
from
the
societal
perspective
.
Sensitivity
analyses
were
performed
.
In
the
base-case
analysis
,
assuming
a
2
.
0
%
probability
of
ACC
for
a
4
-
cm
tumor
,
surgery
was
more
cost-effective
than
surveillance
(
ICER
$
25
,
843
/
LYS
)
.
Both
surgery
and
surveillance
were
incrementally
more
cost-effective
than
sign-off
(
$
35
/
LYS
and
$
8
/
LYS
,
respectively
)
.
Sensitivity
analysis
demonstrated
that
the
model
was
sensitive
to
patient
age
,
tumor
size
,
probability
of
ACC
,
mortality
of
ACC
,
and
cost
of
hospitalization
.
The
results
of
the
model
were
stable
across
different
cost
and
complications
related
to
adrenalectomy
,
regardless
of
operative
approach
.
In
our
model
,
adrenalectomy
was
cost-effective
for
neoplasms
>
4
cm
and
in
patients
<
65
years
,
primarily
owing
to
the
aggressiveness
of
ACC
.
Current
AACE
/
AAES
guideline
recommendations
for
the
resection
of
adrenal
incidentalomas
≥
4
cm
seem
to
be
cost-effective
.
Diseases
Validation
Diseases presenting
"aggressiveness"
symptom
adrenal incidentaloma
cholangiocarcinoma
cushing syndrome
cutaneous mastocytosis
esophageal squamous cell carcinoma
pleomorphic liposarcoma
primary effusion lymphoma
wolf-hirschhorn syndrome
This symptom has already been validated